Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1, 3, 4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway. Issue 14 (15th July 2019)

• Record Type: Journal Article
• Authors: Li, Weiwei; Chu, Jianjie; Fan, Tingting; Zhang, Wei; Yao, Minna; Ning, Zeqiong; Wang, Mingming; Sun, Jin; Zhao, Xian; Wen, Aidong
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 29:Issue 14(2019)
• Page Start: 1831
• Page End: 1835
• Publication Date: 2019-07-15
• Subjects: 1-Phenyl-3-(5-(pyrimidin-4-ylthio)-1, 3, 4-thiadiazol-2-yl)urea derivatives -- Chronic myeloid leukemia (CML) -- Cellular toxicity -- K562 cell -- PI3K/Akt signal pathway; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2019.05.005
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: In this investigation, a series of 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1, 3, 4- thiadiazol-2-yl)urea receptor tyrosine kinase inhibitors were synthesized by a simple and efficient structure-based design. Structure-activity relationship (SAR) analysis of these compounds based on cellular assays led to the discovery of a number of compounds that showed potent activity against human chronic myeloid leukemia (CML) cell line K562, but very weak or no cellular toxicity through monitoring the growth kinetics of K562 cell during a period of 72 h using the real-time live-cell imaging. Among these compounds, 1-(5-((6-((3-morpholinopropyl) amino)pyrimidin-4-yl)thio)-1, 3, 4-thiadiazol-2-yl)-3-(4-(trifluoromethyl)phenyl)urea (7 ) exhibited the least cellular toxicity and better biological activity in cellular assays (K562, IC50 : 0.038 μM). Compound 7 also displayed very good induced-apoptosis effect for human CML cell line K562 and exerted its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway by Human phospho-kinase array analysis. In vitro results indicate that 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1, 3, 4- thiadiazol-2-yl)urea derivatives are lead molecules for further development as treatment of chronic myeloid leukemia and cancer.